Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.30 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.30 |
| ▸ | CDK2 | P24941 | 2/20 | 0.30 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17182868 | 0.77 | CDK2 (0.31) | PDE4DGSK3BCDK2 | |
| SCHEMBL17182914 | 0.76 | PDE4D (0.32) | PDE4DCHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL17182882 | 0.73 | PDE4D (0.34) | PDE4DGSK3BCHEK1CCNA2CDK2 | |
| SCHEMBL17182928 | 0.73 | PDE4D (0.37) | PDE4DGSK3BCHEK1CCNA2CDK2 | |
| SCHEMBL17182866 | 0.73 | PDE4D (0.40) | PDE4DGSK3BCHEK1CCNA2CDK2 | |
| SCHEMBL17182839 | 0.71 | GSK3B (0.39) | PDE4DGSK3BCDK2MEN1KMT2A | |
| SCHEMBL17182921 | 0.71 | PDE4D (0.35) | PDE4DGSK3BCHEK1CCNA2CDK2 | |
| SCHEMBL15718407 | 0.70 | PDE4D (0.42) | PDE4DGSK3BCDK2 | |
| SCHEMBL17182871 | 0.70 | GPR119 (0.33) | PDE4D | |
| SCHEMBL15718900 | 0.68 | TTK (0.33) | PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9573954-B2 | Pyrazolopyrimidine compounds | UNIVERSITY HEALTH NETWORK (CA) | 2017-02-21 | — | — | US | disclosed |
| US-20150299203-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2015-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299203-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | CYP3A5, CYP3A7, DPYD | PDE4D 520/4885GSK3B 3725/4885CHEK1 3400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.